君实生物(01877.HK)：”偌考奇拜单抗注射液“上市申请获受理

Core Viewpoint - Junshi Biosciences has received a notice of acceptance from the National Medical Products Administration for its new drug application for JS005, a monoclonal antibody injection for treating moderate to severe plaque psoriasis in adults [1] Drug Information - Drug Name: JS005 (Rocacitinib Injection) - Application Type: Domestic production drug registration and marketing license - Acceptance Numbers: CXSS2500129, CXSS2500130 - Applicant: Junshi Biosciences - Specifications: 150mg (1ml) per pre-filled syringe and 150mg (1ml) per pre-filled autoinjector [1] - Approval Conclusion: The application has been accepted following the review under Article 32 of the Administrative Licensing Law of the People's Republic of China [1]